Biosimilars: Are they really safe?

June M. McKoy, Francis Joseph Giles*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages61-73
Number of pages13
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume171
ISSN (Print)0927-3042

Keywords

  • Adverse events
  • Biosimilars
  • Cancer
  • Regulatory approval

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Biosimilars: Are they really safe?'. Together they form a unique fingerprint.

Cite this